Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a two-part clinical study titled ‘A Two-Part First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Subcutaneous Doses of GUB014295 in Lean to Overweight or Obese But Otherwise Healthy Men and Women.’ The primary goal is to evaluate the safety and tolerability of GUB014295, a long-acting amylin analogue, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics. This study is significant as it aims to explore potential treatments for overweight conditions in otherwise healthy individuals.
The intervention being tested is GUB014295, administered as a subcutaneous dose. It is designed to act as an amylin analogue, potentially offering new therapeutic options for weight management.
The study follows a randomized, sequential intervention model with triple masking, ensuring that participants, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose of this Phase 1 study is treatment-focused, assessing the initial safety and pharmacokinetic profile of GUB014295.
The study began on November 8, 2023, with a primary completion date yet to be announced. The latest update was submitted on September 16, 2025, indicating ongoing progress. These timelines are crucial for investors tracking the development and potential market entry of new treatments.
For investors, the progress of this study could influence AbbVie’s stock performance, as successful outcomes may enhance the company’s portfolio in the weight management sector. The involvement of Quotient Sciences as a collaborator also highlights industry interest in this area. Competitors in the weight management and obesity treatment market may need to monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.